AnaptysBio (NASDAQ:ANAB) Stock Price Down 3.3%

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) dropped 3.3% during mid-day trading on Monday . The stock traded as low as $25.45 and last traded at $25.69. Approximately 72,883 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 334,471 shares. The stock had previously closed at $26.58.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ANAB shares. SVB Leerink started coverage on AnaptysBio in a report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 target price on the stock. BTIG Research started coverage on AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 target price on the stock. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. Wells Fargo & Company started coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Stock Down 3.0 %

The company has a market cap of $704.04 million, a PE ratio of -4.24 and a beta of -0.32. The business has a 50-day simple moving average of $22.91 and a 200-day simple moving average of $20.86.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares in the company, valued at $17,132,541.86. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares of the company’s stock, valued at approximately $81,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 153,940 shares of company stock valued at $3,513,773. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently bought and sold shares of the stock. Fisher Asset Management LLC boosted its stake in AnaptysBio by 0.7% in the fourth quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 500 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of AnaptysBio in the first quarter valued at about $38,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 2,051 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,381 shares during the last quarter. Finally, Algert Global LLC raised its holdings in shares of AnaptysBio by 40.2% in the third quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 4,740 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.